Improving Drug-Therapy Decisions through Educational Outreach: A Randomized Controlled Trial of Academically Based Detailing

New England Journal of Medicine

Volumn 308, Issue 24, 1983, Pages 1457-1463

  Avorn, Jerry ^a   Soumerai, Stephen B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; DEXTROPROPOXYPHENE; VASODILATOR AGENT;

COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; EDUCATION; HUMAN; NORMAL HUMAN; PRESCRIPTION; THERAPY;

EID: 0020598315     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198306163082406     Document Type: Article

References (42)

1. Cochrane AL. Effectiveness and efficiency: random reflections on health services. London: Nuffield Provincial Hospitals Trust, 1972.
2. Bunker JP, Barnes BA, Mosteller F, eds. Costs, risks, and benefits of surgery. New York: Oxford University Press, 1977.
3. Hiatt H. Protecting the medical commons: who is responsible? N Engl J Med 1975; 293: 235–241.
4. Smits HL. The PSRO in perspective. N Engl I Med 1981; 305: 253–259.
5. Freidson E. Professional dominance; the social structure of medical care. New York: Atherton Press, 1970.
6. Lewis CE, Hassanein RS. Continuing medical education — an epidemiologic evaluation. N Engl J Med 1970; 282: 254–259.
7. Greene R, Simmons J. Improving physician performance. In: Greene R, ed. Assuring quality in medical care: the state of the art. Cambridge, Mass.: Ballinger, 1976:173–189.
8. Temin P. Taking your medicine: drug regulation in the United States. Cambridge, Mass.: Harvard University Press, 1980.
9. Castle M, Wilfert CM, Cate TR, Osterhout S. Antibiotic use at Duke University Medical Center. JAMA 1977; 237: 2819–2822.
10. Scheckler WE, Bennett JV. Antibiotic usage in seven community hospitals. JAMA 1970; 213: 264–267.
11. Stewart RB, Cluff LE, Philp JR, eds. Drug monitoring: a requirement for responsible drug use. Baltimore: Williams & Wilkins, 1977.
12. Maugh TH II. A new wave of antibiotics builds. Science 1981; 214: 1225–1228.
13. Silverman M, Lee PR. Pills, profits, and politics. Berkeley, Calif.: University of California Press, 1974:54–57.
14. Hemminki E. Content analysis of drug detailing by pharmaceutical representatives. Med Educ 1977; 11: 210–215.
15. Smith MC. Principles of pharmaceutical marketing. Philadelphia: Lea & Febiger, 1975.
16. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982; 73: 4–8.
17. Hall D. Prescribing as social exchange. In: Mapes R, ed. Prescribing practice and drug usage. London: Croom Helm, 1980:39–57.
18. Heath C. On prescription-writing in social interaction. In: Mapes R, ed. Prescribing practice and drug usage. London: Croom Helm. 1980:58–69.
19. Miller RR. Propoxyphene: a review. In: Miller RR, Greenblatt D, eds. Drug therapy reviews. Vol 2. New York: Elsevier, 1979:218–257.
20. Moertel CG, Ahmann DL, Taylor WF, Schwartau N. A comparative evaluation of marketed analgesic drugs. N Engl J Med 1972; 286: 813–815.
21. Tennant FS Jr. Drug abuse in the U.S. Anny, Europe. JAMA 1972; 221: 1146–1149.
22. United States National Center for Health Statistics. Drugs most frequently used in office-based practice: National Ambulatory Medical Care Survey, 1980. Hyattsville, Md.: National Center for Health Statistics, 1982. (Advance data from vital and health statistics. No. 78) (DHHS publication no. (PHS)82–1250).
23. American Medical Association. AMA drug evaluations. 4th ed. New York: John Wiley, 1980:214–215.
24. Needleman P, Johnson EM Jr. Vasodilators and the treatment of angina. In: Gilman AG, Goodman LS, Gilman A, eds. The pharmacological basis of therapeutics. 6th ed. New York: Macmillan, 1980:819–833.
25. Yesavage JA, Tinklenberg JR, Hollister LE, Berger PA. Vasodilators in senile dementias: a review of the literature. Arch Gen Psychiatry 1979; 36: 220–223.
26. Coffman JD. Vasodilator drags in peripheral vascular disease. N Engl J Med 1979;300: 713–717.
27. Kunin CM, Tupasi T, Craig WA. Use of antibiotics: a brief exposition of the problem and some tentative solutions. Ann Intern Med 1973: 79: 555–560.
28. Noel MW, Paxinos J. Cephalosporins: use review and cost analysis. Am J Hosp Pharm 1978; 35: 933–935.
29. Karlins M, Abelson HI. Persuasion: how opinions and attitudes are changed. 2nd ed. New York: Springer, 1970.
30. Hovland CI. Lumsdaine AA, Sheffield FD. Experiments on mass communication. Princeton, N.J.: Princeton University Press, 1949.
31. Watts WA. Relative persistence of opinion change induced by active compared to passive participation. J Pers Soc Psychol 1967; 5: 4–15.
32. Coleman JS, Katz E, Menzel H. Medical innovation: a diffusion study. Indianapolis: Bobbs-Merrill, 1966.
33. Levethal H, Cleary PD. The smoking problem: a review of the research and theory in behavioral risk modification. Psychol Bull 1980; 88: 370–405.
34. Sackett DL, Haynes RB, eds. Compliance with therapeutic regimens. Baltimore: Johns Hopkins University Press, 1976.
35. Eisenberg JM, Williams SV. Cost containment and changing physicians' practice behavior: can the fox learn to guard the chicken coop? JAMA 1981; 246: 2195–2201.
36. Luft HS. Assessing the evidence on HMO performance. Milbank Mem Fund Q 1980; 58: 501–536.
37. “Opren scandal.” Lancet 1983; 1: 219–220.
38. Prescription drug coverage within publicly financed health insurance programs. Washington, D.C.: Pharmaceutical Manufacturers' Association, 1983.
39. McDonald CJ. Protocol-based computer reminders, the quality of care and the non-perfectibility of man. N Engl J Med 1976; 295: 1351–1355.
40. Barnett GO, Winickoff R, Dorsey JL, Morgan MM, Lurie RS. Quality assurance through automated monitoring and concurrent feedback using a computer-based medical Information system. Med Care 1978; 16: 962–970.
41. Rucker TD. Drug information for prescribers and dispensers: toward a model system. Med Care 1976; 14: 156–165.
42. Culff L. The prescribing habits of physicians. Hosp Prac 1967; 2 (9): 100–104.